

Setting a New Standard of Care in Advanced Lung Cancer

Saturday, 20 October 2018
13:00 – 14:30

Satellite Symposium
Sponsored by MSD

Messe Munich
ICM – Room 14b
Munich, Germany

Chair: Corey Langer (USA)

CHAIR

Corey Langer

Professor of Medicine
Director of Thoracic Oncology
University of Pennsylvania
Philadelphia, Pennsylvania, USA

FACULTY

Marina Garassino

Chief of Medical Thoracic Oncology Unit
Istituto Nazionale dei Tumori di Milano
Milan, Italy

Giorgio Scagliotti

Professor and Chair of Medical Oncology
University of Turin and San Luigi Hospital
Orbassano, Italy

Educational Objectives

- Review the current immune checkpoint inhibitor treatment landscape for patients with advanced NSCLC
- Gain an understanding of the rationale of combination therapy and the future of combination strategies in the treatment of patients with lung cancer
- Consider the potential for use of these agents and treatment strategies in early-stage NSCLC

AGENDA

| | | |
|---------------|--|--------------------|
| 13:00 | Welcome and Introduction | Corey Langer |
| 13:00 – 13:20 | Treatment Options in 1L Metastatic NSCLC: What Are the Roles of Combination and Monotherapy in Metastatic Disease? | Marina Garassino |
| 13:20 – 13:40 | Tumor Expression: Where Are We Today in NSCLC? | Corey Langer |
| 13:40 – 14:00 | Use of Immune Checkpoint Inhibitors in Early-Stage NSCLC – Next-Generation Trials in NSCLC | Giorgio Scagliotti |
| 14:00 – 14:30 | Patient Selection and Panel Discussion | Faculty |
| 14:30 | Closing Remarks | Corey Langer |